The Dow Jones surged 900 points today in response to positive news about a coronavirus candidate vaccine being developed by Moderna Therapeutics. Early this morning, the company reported that eight patients in a phase 1 safety trial of its vaccine generated neutralizing antibodies to the virus comparable to the levels found in people who had recovered from infection. Basically, the vaccine produces an immune response equal to that provoked by natural infection with the virus.
Moderna’s vaccine is based on a synthetic version of the messenger RNA (mRNA) that the coronavirus uses to construct the proteins that enable it to
Read more Source: reason.com